Browse by Nurse Practitioner Items

Nurse practitioner PBS prescribing

MEDICINES WHICH MAY BE PRESCRIBED BY AUTHORISED NURSE PRACTITIONERS

From 1 September 2010, nurse practitioners endorsed to prescribe under state or territory legislation can apply for approval as PBS prescribers (authorised nurse practitioners) Information for nurse practitioners to become authorised PBS prescribers is available from the Department of Human Services.

The medicines listed for prescribing by authorised nurse practitioners from 1 November 2010 are identified by ‘NP’ in the PBS Schedule. Nurse practitioners must not write PBS prescriptions for other medicines.

PBS prescribing is limited by a nurse practitioner’s scope of practice, and state and territory prescribing rights. Prescribing of PBS medicines is also contingent on a prescriber being an authorised nurse practitioner and having collaborative arrangements in place, as required by amendments to the National Health Act 1953.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations to the Minister for Health regarding medicines for prescribing by authorised nurse practitioners.

Further to prescribing within collaborative arrangements, certain medicines also have additional conditions for prescribing by nurse practitioners, as recommended by the PBAC. These medicines are identified by the codes ‘CTO’ for continuation therapy only or ‘SCM’ for prescribing within a shared care model, as outlined below:

  • Continuing therapy only model

Where the patient’s treatment and prescribing of a medicine has been initiated by a medical practitioner, but prescribing is continued by a nurse practitioner. (This is similar to existing arrangements between specialists and medical practitioners for prescribing certain medicines.)

  • Shared care model

Where care is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed plan to manage the patient, in a patientcentred model of care. The details surrounding shared care arrangements will depend on the practitioners involved, patient needs and the healthcare context.

Some medicines are included in more than one section of the Schedule, and for more than one prescriber type. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their prescriber type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Nurse practitioner PBS prescriptions are identifiable by colour, and include the indicator ‘NP’ on personalised forms and a tick box on non-personalised (blank) forms.

Prescriptions must include the nurse practitioner’s PBS prescriber number. For unrestricted and restricted PBS medicines, midwives/nurse practitioners can use the personalised or non-personalised PBS prescriber forms.  For authority required and authority required (streamlined) PBS medicines, midwives/nurse practitioners can use the authority personalised or non-personalised PBS prescriber forms.  Nurse practitioner PBS prescriptions may include repeats. 

Regulation 49 applies for nurse practitioner prescribing. A nurse practitioner can direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time, if certain conditions are satisfied.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from the Department of Human Services for each prescription. (Refer to Prescribing Medicines — Information for PBS prescribers and Supplying medicines — What Pharmacists Need to Know, for more information on authority prescriptions.)

State and territory requirements: Nurse practitioners may prescribe medicines as private prescriptions according to their state/territory prescribing accreditation. The medicines which can be prescribed differ between states and territories. It is the nurse practitioner’s responsibility to ensure adherence to State/Territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS prescriptions.

  • Legend
  • PPalliative care items
  • MPMedical Practitioner
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MPNP 2763K HALOPERIDOLhaloperidol 2 mg/mL oral liquid, 100 mL 1 1 5
MPNP 2770T HALOPERIDOLhaloperidol 5 mg tablet, 50 1 50 5
MPNP 2761H HALOPERIDOLhaloperidol 500 microgram tablet, 100 1 100 5
MPNP 2768Q HALOPERIDOLhaloperidol 5 mg/mL injection, 10 x 1 mL ampoules 1 10 0
MPNP 3456X HALOPERIDOLhaloperidol 5 mg/mL injection, 10 x 1 mL ampoules 1 10 0
MPNP 2767P HALOPERIDOLhaloperidol 1.5 mg tablet, 100 1 100 5
MPNP 2766N HALOPERIDOL DECANOATEhaloperidol (as decanoate) 150 mg/3 mL injection, 5 x 3 mL ampoules 1 5 0
MPNP 2765M HALOPERIDOL DECANOATEhaloperidol (as decanoate) 50 mg/mL injection, 5 x 1 mL vials 1 5 0
MPNP 1463B HEPARIN SODIUMheparin sodium 5000 units/5 mL injection, 50 x 5 mL ampoules 1 50 5
MPNP 1076P HEPARIN SODIUMheparin sodium 35 000 units/35 mL injection, 35 mL vial 12 12 5
MPNP 1466E HEPARIN SODIUMheparin sodium 5000 units/0.2 mL injection, 5 x 0.2 mL ampoules 1 5 5
MPNP 10185C HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATEhigh fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (4:1 ratio long chain fat to carbohydrate plus protein) oral liquid, 32 x 200 mL cartons 5 5 5
MPNP 2652N HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATEhigh fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (3:1 ratio long chain fat to carbohydrate plus protein) powder for oral liquid, 300 g 24 24 5
MPNP 11108P HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATEhigh fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate oral semi-solid, 48 x 100 g tubs 3 3 5
MPNP 9446E HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATEhigh fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (4:1 ratio long chain fat to carbohydate plus protein) powder for oral liquid, 300 g 24 24 5
MPNP 1640H HYDRALAZINEhydralazine hydrochloride 25 mg tablet, 100 2 200 2
MPNP 1639G HYDRALAZINEhydralazine hydrochloride 50 mg tablet, 100 2 200 2
MPNP 1484D HYDROCHLOROTHIAZIDEhydrochlorothiazide 25 mg tablet, 100 1 100 1
MPNP 1280J HYDROCHLOROTHIAZIDE + TRIAMTERENEhydrochlorothiazide 25 mg + triamterene 50 mg tablet, 100 1 100 1
MPNP 1499X HYDROCORTISONEhydrocortisone 4 mg tablet, 50 1 50 4
MPNP 1500Y HYDROCORTISONEhydrocortisone 20 mg tablet, 60 1 60 4
MPNP 2441L HYDROCORTISONE ACETATEhydrocortisone acetate 1% eye ointment, 5 g 1 1 0
MPNP 1502C HYDROCORTISONE ACETATEhydrocortisone acetate 10% enema, 21.1 g 2 2 3
MPNP 2881P HYDROCORTISONE ACETATEhydrocortisone acetate 1% cream, 50 g 1 1 1
MPNP 2882Q HYDROCORTISONE ACETATEhydrocortisone acetate 1% ointment, 50 g 1 1 1
MPNP 1511M HYDROCORTISONE SODIUM SUCCINATEhydrocortisone (as sodium succinate) 250 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack 6 6 0
MPNP 3096Y HYDROCORTISONE SODIUM SUCCINATEhydrocortisone (as sodium succinate) 250 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack 1 1 0
MPNP 3471Q HYDROCORTISONE SODIUM SUCCINATEhydrocortisone (as sodium succinate) 250 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack 1 1 0
MPNP 1501B HYDROCORTISONE SODIUM SUCCINATEhydrocortisone (as sodium succinate) 100 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack 2 2 0
MPNP 1510L HYDROCORTISONE SODIUM SUCCINATEhydrocortisone (as sodium succinate) 100 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack 6 6 0
MPNP 3470P HYDROCORTISONE SODIUM SUCCINATEhydrocortisone (as sodium succinate) 100 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack 2 2 0
MPNP 8542N HYDROMORPHONEhydromorphone hydrochloride 4 mg tablet, 20 1 20 0
MPNP 8420E HYDROMORPHONEhydromorphone hydrochloride 2 mg/mL injection, 5 x 1 mL ampoules 1 5 0
MPNP 8543P HYDROMORPHONEhydromorphone hydrochloride 8 mg tablet, 20 1 20 0
MPNP 9409F HYDROMORPHONEhydromorphone hydrochloride 64 mg modified release tablet, 14 1 14 0
MPNP 8421F HYDROMORPHONEhydromorphone hydrochloride 10 mg/mL injection, 5 x 1 mL ampoules 1 5 0
MPNP 9406C HYDROMORPHONEhydromorphone hydrochloride 8 mg modified release tablet, 14 1 14 0
MPNP 9299K HYDROMORPHONEhydromorphone hydrochloride 4 mg modified release tablet, 14 1 14 0
MPNP 11467M HYDROMORPHONEhydromorphone hydrochloride 1 mg/mL oral liquid, 200 mL 1 1 0
MPNP 9408E HYDROMORPHONEhydromorphone hydrochloride 32 mg modified release tablet, 14 1 14 0
MPNP 8424J HYDROMORPHONEhydromorphone hydrochloride 1 mg/mL oral liquid, 473 mL 1 1 0
MPNP 8541M HYDROMORPHONEhydromorphone hydrochloride 2 mg tablet, 20 1 20 0
MPNP 9407D HYDROMORPHONEhydromorphone hydrochloride 16 mg modified release tablet, 14 1 14 0
MPNP 2162T HYDROXOCOBALAMINhydroxocobalamin 1 mg/mL injection, 3 x 1 mL ampoules 1 3 0
MPNP 9048F HYDROXOCOBALAMINhydroxocobalamin 1 mg/mL injection, 3 x 1 mL ampoules 1 3 0
MPNP 1512N HYDROXYCHLOROQUINEhydroxychloroquine sulfate 200 mg tablet, 100 1 100 1
MPNP 3473T HYOSCINE BUTYLBROMIDEhyoscine butylbromide 20 mg/mL injection, 5 x 1 mL ampoules 1 5 0
MPNP 5317W HYOSCINE BUTYLBROMIDEhyoscine butylbromide 20 mg/mL injection, 5 x 1 mL ampoules 6 30 3
MPNP 2956N HYPROMELLOSEHYPROMELLOSE Eye drops 5 mg per mL (0.5%), 15 mL, 1 1 1 5
MPNP 8287E HYPROMELLOSEHYPROMELLOSE Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative), 1 1 1 5
MPNP 8564R HYPROMELLOSE + CARBOMER-980hypromellose 0.3% + carbomer-980 0.2% eye gel, 10 g 1 1 5